Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression

Leukemia volume 19, pages 1289–1291 (2005)Cite this article

TO THE EDITOR

In recent years it has become evident that there are two major subgroups of chronic lymphocytic leukemia (CLL) based on IgVH mutational status of the CLL leukemic cells.1 CLL patients with unmutated IgVH generally have more aggressive disease characterized by clinical progression, a more advanced stage and a shorter overall survival.1 Recently, using DNA microarray analysis it has been shown that ZAP-70 is highly expressed in CLL patients with unmutated status, while the mutated group usually has low ZAP-70 expression.2 Subsequent studies with larger numbers of CLL patients demonstrated that ZAP-70 expression in CLL cells can predict the mutational status, and that ZAP-70 levels also correlate with disease progression, and overall survival.3, 4

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  2. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.

    Article  CAS  PubMed  Google Scholar 

  4. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111.

    Article  CAS  PubMed  Google Scholar 

  5. Chan AC, Iwashima M, Turck CW, Weiss A . ZAP-70: a 70 kD protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649–662.

    Article  CAS  PubMed  Google Scholar 

  6. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614.

    Article  CAS  PubMed  Google Scholar 

  7. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004; 124: 315–324.

    Article  CAS  PubMed  Google Scholar 

  8. Guarini A, Riera L, Cignetti A, Montacchini L, Massaia M, Foa R . Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 1997; 89: 212–218.

    CAS  PubMed  Google Scholar 

  9. Totterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K . T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989; 74: 786–792.

    CAS  PubMed  Google Scholar 

  10. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Y Herishanu and S Kay: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Y Herishanu, S Kay, O Rogowski, M Pick, E Naparstek & V R Deutsch

  2. Department of Hematology Hadassah University Hospital, Jerusalem, Israel

    A Polliack

Authors
  1. Y Herishanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Kay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Rogowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Pick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Naparstek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V R Deutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Polliack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Herishanu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herishanu, Y., Kay, S., Rogowski, O. et al. T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. Leukemia 19, 1289–1291 (2005). https://doi.org/10.1038/sj.leu.2403762

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403762

This article is cited by

Search

Advanced search

Quick links